Research scope: This page describes published research and analytical questions. It does not provide medical advice, dosing, administration instructions, or a recommendation to purchase or use any product.
Deep evidence reviewRead the full Hexarelin evidence review →Separate receptor findings, animal cardiovascular models, small human studies, and supplier-documentation limits.

For laboratory research only

Compare Hexarelin research suppliers

Listings now default to lowest tracked price per mg. The highlighted price badge is a catalog-price signal only, not a quality, safety, or documentation ranking.

1 exact listings

The document count covers six basic checks. “Not found” means we could not confirm it from the public records we reviewed—not that the testing never happened.

Affiliate disclosure: Some links may earn PDD a commission. Affiliate status does not change what we report or how suppliers are ordered.

Best tracked price per mg · €5.36/mg

Particle Peptides

2 of 6 fields documentedReview recommended

Hexarelin (5 mg)

Exact name catalog match · Affiliate relationship · Price badge is not an overall recommendation

Listed price

€26.82

€5.36 per mg

In stock

Best-price badges use the listed catalog price per mg in the current comparison view, grouped by currency and preferring in-stock listings. Prices exclude shipping and tax. Public-code estimates appear only where the percentage is documented. Price and documentation coverage do not establish identity, purity, sterility, safety, or suitability.

How Hexarelin is used in research

Hexarelin activates the growth-hormone secretagogue receptor and has been used to investigate pituitary GH release and receptor pharmacology.

Experimental literature also includes cardiovascular and cellular models, but these mechanistic findings do not establish an approved clinical use.

Ghrelin-receptor signalingGrowth-hormone releaseCardiovascular models

Evidence map

Research stage matters. Findings from one model should not be silently promoted to another.

Laboratory

Receptor and cell studies examine secretagogue signaling.

Animal

Endocrine and cardiovascular models have been reported.

Human

Small physiological studies measured hormone responses; no FDA-approved drug exists.

What the evidence does not establish

Hormone-response studies are generally small and short. Cardiovascular model findings should not be interpreted as demonstrated clinical outcomes.

Study findings also do not authenticate a supplier’s material. Biological plausibility, a familiar name, or a published paper cannot substitute for lot-specific identity and quality evidence.

Analytical and documentation checks

The test plan should match the exact molecule, modification, and research question.

  • Confirm the six-residue sequence and chemical form.
  • Check identity separately from purity and content.
  • Require current-lot documentation rather than a generic reference spectrum.

At minimum, connect the product name, sequence, sample identifier, lot, report, method, expected result, and observed result. Record untested attributes as “not reported,” not as assumed passes.

Build the documentation record

Regulatory status

Hexarelin is not an FDA-approved drug and remains an investigational research compound.

Regulatory status can change and attaches to specific products and jurisdictions. Verify current official records before publishing, procuring, or relying on a status claim.

Primary sources and official records

Use these records as starting points, then assess the exact model, test article, methods, and date:

Peptide Due Diligence Research Brief

Follow the evidence, not the headline.

Receive new evidence maps, documentation guides, and material corrections as the directory expands.

By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.

Already subscribed? Get your free checklist.

Related peptide research pages